search
Back to results

Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes (Lymphoscreen)

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood samplings
Sponsored by
Nantes University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Type 1 Diabetes

Eligibility Criteria

7 Years - 70 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria:

  • at least, 50 patients with "recent" type 1 diabetes,
  • 30 patients with long-term type 1 diabetes,
  • 10 patients with Latent Autoimmune Diabetes,
  • 10 subjects with a risk for diabetes,
  • 20 type 1 diabetic patients with pancreatic graft or Langerhans islet graft.
  • 50 healthy subjects paired to HLA class I and to the age

Those subjects have to respect the following criteria :

  • Age from 7 to 70 -Caucasian
  • Affiliated to a national insurance scheme
  • Written informed consent obtained For children, written informed consent is required from the two parents.

Non-inclusion criteria :

  • Age strictly inferior to 7 or strictly superior to 70 years old
  • Pregnancy
  • Secondary diabetes
  • No written informed consent

Sites / Locations

  • CHU de Nantes

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Active Comparator

Experimental

Experimental

Experimental

Experimental

Arm Label

Long-term type 1 diabetic patients

control patients

diabetic and transplanted patients

subjects with high risk for diabetes

patients with recent type 1 diabetes

patients with Latent Autoimmune Diabetes

Arm Description

Long-term type 1 diabetic patients

control patients

diabetic and transplanted patients

subjects with high risk for diabetes

patients with recent type 1 diabetes

patients with Latent Autoimmune Diabetes

Outcomes

Primary Outcome Measures

Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012)

Secondary Outcome Measures

Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).

Full Information

First Posted
January 4, 2010
Last Updated
September 7, 2015
Sponsor
Nantes University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01042301
Brief Title
Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes
Acronym
Lymphoscreen
Official Title
Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2015
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The "Lymphoscreen" study aims to characterize precisely (phenotypes/cytokines/functions) CD8+ T cell responses in type 1 Diabetes to identify biomarkers of the disease. Such markers are needed for refine type 1 Diabetes diagnosis/prognostic, and to design new therapeutic approaches targeting autoreactive CD8+ T cells. An original approach using DNA immunization of humanized mice allowed us to identify relevant CD8 epitopes derived from GAD65 and IA-2 beta cell autoantigens. The aims are: (i) identifying exhaustively epitopes recognized by autoreactive CD8+ T lymphocytes in type 1 Diabetes and following islet or pancreas graft in humans; (ii) identifying pathogenic CD8+ T cell patterns or profiles related to type 1 Diabetes pathogenesis and evolution; (iii) correlating CD8+ autoreactive T cell responses and autoantibody responses to new cellular (such as CD4+ T cells or peripheral cell miRNA) or humoral markers of the disease (such as serum miRNA).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Long-term type 1 diabetic patients
Arm Type
Experimental
Arm Description
Long-term type 1 diabetic patients
Arm Title
control patients
Arm Type
Active Comparator
Arm Description
control patients
Arm Title
diabetic and transplanted patients
Arm Type
Experimental
Arm Description
diabetic and transplanted patients
Arm Title
subjects with high risk for diabetes
Arm Type
Experimental
Arm Description
subjects with high risk for diabetes
Arm Title
patients with recent type 1 diabetes
Arm Type
Experimental
Arm Description
patients with recent type 1 diabetes
Arm Title
patients with Latent Autoimmune Diabetes
Arm Type
Experimental
Arm Description
patients with Latent Autoimmune Diabetes
Intervention Type
Other
Intervention Name(s)
Blood samplings
Primary Outcome Measure Information:
Title
Identification and characterization of new CD8+ T lymphocytes related to type 1 diabetes and its evolution (2009-2012)
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Identification and characterization of new profiles of humoral and cellular markers (including T cell reactivity and miRNA) related to type 1 diabetes (2010-2014).
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria: at least, 50 patients with "recent" type 1 diabetes, 30 patients with long-term type 1 diabetes, 10 patients with Latent Autoimmune Diabetes, 10 subjects with a risk for diabetes, 20 type 1 diabetic patients with pancreatic graft or Langerhans islet graft. 50 healthy subjects paired to HLA class I and to the age Those subjects have to respect the following criteria : Age from 7 to 70 -Caucasian Affiliated to a national insurance scheme Written informed consent obtained For children, written informed consent is required from the two parents. Non-inclusion criteria : Age strictly inferior to 7 or strictly superior to 70 years old Pregnancy Secondary diabetes No written informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lucy Chaillous
Organizational Affiliation
Nantes University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France

12. IPD Sharing Statement

Learn more about this trial

Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes

We'll reach out to this number within 24 hrs